Related Experiment Video
Updated: Feb 20, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Direct analysis of tumor-associated peptide antigens
C L Slingluff1, D F Hunt, V H Engelhard
1University of Virginia Health Sciences Center, Charlottesville.
Abstract:
Adoptive immunotherapy with tumor-specific cytotoxic T lymphocytes (CTLs) can induce tumor regressions in animals and in human cancer patients. Antigens recognized by CTLs from cancer patients are being sought as possible immunogens, a number of which have been identified during the past year. The ultimate result may be the development of novel peptide-based immunotherapies and a new understanding of the T-cell response to human cancer.
Insights
Adoptive immunotherapy using tumor-specific cytotoxic T lymphocytes (CTLs) shows promise for treating cancer. Identifying cancer antigens recognized by CTLs could lead to new peptide-based treatments and a better understanding of anti-cancer T-cell responses.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Adoptive immunotherapy utilizes tumor-specific cytotoxic T lymphocytes (CTLs).
- This approach has demonstrated the ability to induce tumor regressions in both animal models and human cancer patients.
- Identifying the specific antigens that CTLs recognize is crucial for advancing this therapy.
Purpose of the Study:
- To explore the potential of adoptive immunotherapy in cancer treatment.
- To identify tumor antigens recognized by cytotoxic T lymphocytes (CTLs) from cancer patients.
- To pave the way for novel peptide-based immunotherapies and enhance understanding of T-cell responses in human cancer.
Main Methods:
- Utilizing adoptive immunotherapy with tumor-specific cytotoxic T lymphocytes (CTLs).
- Actively seeking and identifying antigens recognized by CTLs from cancer patients.
- Investigating the T-cell response to human cancer.
Main Results:
- Tumor regressions have been observed in animal models and human cancer patients treated with adoptive immunotherapy.
- Several tumor antigens recognized by CTLs have been identified in the past year.
- Progress has been made in understanding the T-cell response to human cancer.
Conclusions:
- Adoptive immunotherapy with CTLs is a viable strategy for inducing tumor regression.
- The identification of tumor antigens is a critical step towards developing effective cancer immunotherapies.
- Future developments may include novel peptide-based immunotherapies and a deeper comprehension of anti-cancer T-cell immunity.
